Parkinson’s Research Identified Novel Pathway Activation
Researchers found that some patients without known genetic risks exhibit markers linked to LRRK2 signaling.
Updated on Sept. 26, 2026 in Alzheimer’s
Live Poll
Should medical diagnostics integrate functional pathway testing alongside standard genetic sequencing for patients?
A new study has identified elevated LRRK2 kinase activity in a subset of idiopathic Parkinson's disease patients who lack recognized pathogenic variants. This discovery could help researchers better identify specific patient groups for future targeted therapies.
Why it matters
Identifying patients with elevated LRRK2 activity is a critical step toward developing personalized, LRRK2-targeted treatments for Parkinson's. This research offers a new way to classify patients who might benefit from these emerging therapies.
In a study of 181 genetically enriched Parkinson's patients and 71 controls, researchers quantified Rab10 phosphorylation in neutrophils to measure LRRK2 pathway activity. They found that 14% of patients without recognized pathogenic variants showed elevated pathway activation.
The details
The study utilized whole-exome sequencing to analyze genetic variants and evaluated Rab10 phosphorylation as a biomarker for LRRK2 kinase activity. Researchers also used siRNA knockdown in A549 cells to identify genes like NECAP2 as potential genetic modifiers. By comparing these markers against patients with known VPS35 p.D620N mutations, the team established a threshold for identifying aberrant LRRK2 signaling within the idiopathic population.
Timeline
September 26, 2026: The peer-reviewed research article was published.
Health Landscape
The development of LRRK2-targeted therapies represents a significant shift toward precision medicine in Parkinson's care. This study expands the potential candidate pool for these therapies by identifying pathway activation in patients previously considered idiopathic.
These findings are a research-level development and do not currently change clinical diagnostic protocols or standard treatment plans. If you are managing Parkinson's disease, discuss any emerging genetic testing or clinical trial opportunities with your neurologist.
The takeaway
This study underscores the potential for sub-typing Parkinson's disease through specific kinase activity markers. Tracking ongoing progress in precision medicine for neurological disorders remains a key metric for understanding future treatment access.
Further reading
For broader context on neurodegenerative disease research and emerging diagnostic markers, visit the Alzheimer’s section.
More information
View the complete peer-reviewed research article for detailed findings.
Source note: This article includes information reported by Nature.
Live Poll
Should medical diagnostics integrate functional pathway testing alongside standard genetic sequencing for patients?
